Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person FLT3 N676D [plasma membrane]

Class:Id	EntityWithAccessionedSequence:9702895
_displayName	FLT3 N676D [plasma membrane]
_timestamp	2020-10-02 18:00:21
compartment	[Compartment:876] plasma membrane
created	[InstanceEdit:9702894] Rothfels, Karen, 2020-10-02
disease	[Disease:1500689] cancer [Disease:9630839] acute myeloid leukemia
endCoordinate	993
hasModifiedResidue	[ReplacedResidue:9702893] L-asparagine 676 replaced with L-aspartic acid
literatureReference	[LiteratureReference:9699384] The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
name	FLT3 N676D
referenceEntity	[ReferenceGeneProduct:54914] UniProt:P36888 FLT3 [Homo sapiens]
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9702896] R-HSA-9702895.1
startCoordinate	27
(hasComponent)	[Complex:9702897] FLT3 N676D dimer [plasma membrane] [Homo sapiens]
(hasMember)	[DefinedSet:9699522] sorafenib-sensitive FLT3 mutants [plasma membrane] [Homo sapiens] [DefinedSet:9699525] quizartinib-resistant FLT3 mutants [plasma membrane] [Homo sapiens] [DefinedSet:9699532] sunitinib-sensitive FLT3 mutants [plasma membrane] [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by FLT3 N676D [plasma membrane] (9702895)